Catabasis Pharmaceuticals (CATB) announced Tuesday that the Part B of its MoveDMD trial of edasalonexent, for the treatment of Duchenne muscular dystrophy, did not meet the primary endpoint.
from RTT - Before the Bell http://ift.tt/2k3dcFy
via IFTTT
No comments:
Post a Comment